Summary
H7T1 Chart
HUTCHMED (China) Limited (HCM) HUTCHMED (China) Limited Presents at Deutsche Bank ADR Virtual Investor Conference 2025 Transcript
HUTCHMED (China) Limited ( HCM ) HUTCHMED (China) Limited Deutsche Bank ADR Virtual Investor Conference 2025 November 4, 2025 8:00 AM EST Company Participants David Ng - Head of Investor Relations & Capital Strategies Conference Call Participants Zafar Aziz - Deutsche Bank Aktiengesellschaft Presentation Zafar Aziz Deutsche Bank Aktiengesellschaft Hello, and Welcome to Deutsche Bank's Virtual Investor Conference, dbVIC. This is Zafar Aziz from the Deutsche Bank team.
HUTCHMED (China) Limited (HCM) Discusses Antibody Targeted Therapy Conjugates Platform and Lead Candidate HMPL-A251 in R&D Update Transcript
HUTCHMED (China) Limited ( HCM ) Discusses Antibody Targeted Therapy Conjugates Platform and Lead Candidate HMPL-A251 in R&D Update October 31, 2025 8:00 AM EDT Company Participants David Ng - Head of Investor Relations & Capital Strategies Ming Shi - Executive VP, Head of R&D and Chief Medical Officer Conference Call Participants Alec Stranahan - BofA Securities, Research Division Khalil Fenina - Goldman Sachs Group, Inc., Research Division Yuxi Dong - Jefferies LLC, Research Division Adam McCarter - Cavendish Securities plc, Research Division Presentation David Ng Head of Investor Relations & Capital Strategies Hello, everyone. Good evening and good morning.
HUTCHMED (China) Limited (HCM) Q2 2025 Earnings Call Transcript
HUTCHMED (China) Limited (NASDAQ:HCM ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Chig Fung Cheng - CFO & Executive Director David Ng - Head of Investor Relations & Capital Strategies George Yuan - Corporate Participant Ming Shi - Executive VP, Head of R&D and Chief Medical Officer Wei-Guo Su - CEO, Chief Scientific Officer & Executive Director Conference Call Participants Chen Chen - UBS Investment Bank, Research Division Matthew Yan - Unidentified Company Paul Choi - Goldman Sachs Group, Inc., Research Division David Ng Hello, everyone. This is David Ng, Head of Investor Relations of HUTCHMED.
Hutchmed (China) Limited American Depositary Shares (H7T1) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Hutchmed (China) Limited American Depositary Shares ever had a stock split?
Hutchmed (China) Limited American Depositary Shares Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Chig Fung Cheng BEc, CEO | XBER Exchange | US44842L1035 ISIN |
| HK Country | 1,811 Employees | - Last Dividend | 30 May 2019 Last Split | - IPO Date |
Overview
HUTCHMED (China) Limited specializes in discovering, developing, and commercializing innovative treatments for cancer and immunological diseases, operating on a global scale with a significant presence in Hong Kong. Initially founded in 2000 as Hutchison China MediTech Limited, the company underwent a rebranding to HUTCHMED (China) Limited in May 2021, underscoring its evolution and growing ambitions in the healthcare sector. With its headquarters based in Central, Hong Kong, HUTCHMED has forged strategic collaborations with industry giants such as AstraZeneca, Lilly (Shanghai) Management Company, BeiGene, Innovent Biologics, and several others, facilitating the advancement of its robust pipeline geared towards addressing unmet medical needs in oncological and immunological disorders. Leveraging cutting-edge research and development capabilities, HUTCHMED aims to lead in the creation of targeted therapeutics and immunotherapies, positioning itself as a key player in the fight against some of the most challenging diseases.
Products and Services
- Savolitinib: An innovatively designed inhibitor targeting MET gene mutations, Savolitinib offers a new hope in the treatment of non-small cell lung cancer (NSCLC), various renal cancers, colorectal cancer (CRC), and gastric cancer (GC), providing patients with an option that specifically tackles the genetic basis of their condition.
- Fruquintinib: This highly selective inhibitor focuses on vascular endothelial growth factor receptors (VEGFR), crucial in tumor-induced angiogenesis. It's formulated for the management of CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, alongside various gastrointestinal and solid tumors, presenting a versatile option in anti-cancer care.
- Surufatinib: Targeting a broad spectrum of neuroendocrine tumors (NET), Surufatinib offers therapeutic possibilities for both pancreatic and non-pancreatic NET, biliary tract cancer, sarcoma, among others, by inhibiting angiogenesis and immune evasion pathways.
- Tazemetostat: An EZH2 inhibitor, Tazemetostat is employed in treating specific cases of epithelioid sarcoma and follicular lymphoma, exploiting epigenetic mechanisms to halt tumor growth.
- HMPL-523, HMPL-689, and Other Inhibitors: A diverse range of inhibitors like HMPL-523, targeting spleen tyrosine kinase, and HMPL-689, focusing on phosphoinositide 3'-kinase delta (PI3Kδ), among others, underscore HUTCHMED’s dedication to addressing various hematological cancers and chronic immune diseases with precision medicine.
- Collaborative Projects: In addition to its in-house developed therapies, HUTCHMED’s strategic alliances with pharmaceutical and biotech companies have enabled the development and commercialization of next-generation therapeutics, enhancing its portfolio and therapeutic impact.
Contact Information
